Evidence map›Paper›PMID 38019773›Full record

ArticleAnnals of medicine2023

Combining COVID-19 and seasonal influenza vaccines together to increase the acceptance of newly developed vaccines in the Eastern Mediterranean Region: a cross-sectional study.

Mohamed Fakhry Hussein, Abdelhamid Elshabrawy, Sarah Assem Ibrahim, Suzan Abdel-Rahman, Hoda Ali Ahmed Shiba, Ehab Elrewany, Mohammad Haroon Hairan, Ramy Mohamed Ghazy

Abstract read
In one paragraph

Article in Annals of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohamed Fakhry HusseinOccupational Health and Industrial Medicine Department, High Institute of Public Health, Alexandria University, Alexandria, Egypt.
Abdelhamid ElshabrawyBiostatistics and Demography Department, Faculty of Graduate Studies for Statistical Research, Cairo University, Giza, Egypt.
Sarah Assem IbrahimBiostatistics and Demography Department, Faculty of Graduate Studies for Statistical Research, Cairo University, Giza, Egypt.
Suzan Abdel-RahmanBiostatistics and Demography Department, Faculty of Graduate Studies for Statistical Research, Cairo University, Giza, Egypt.
Hoda Ali Ahmed ShibaPublic Health and Community Medicine at Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt.ORCID 0000-0001-8147-3034
Ehab ElrewanyTropical Health Department, High Institute of Public Health, Alexandria University, Alexandria, Egypt.
Mohammad Haroon HairanDepartment of Natural Resources Management, Faculty of Environment, Kabul University, Kabul, Afghanistan.ORCID 0000-0001-8043-0999
Ramy Mohamed GhazyTropical Health Department, High Institute of Public Health, Alexandria University, Alexandria, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimThe World Health Organization (WHO) recommended the concomitant administration (co-administration) of inactivated seasonal influenza and coronavirus disease 2019 (COVID-19) vaccines, encouraging the practice for the 2021-2022 flu season. This study aimed to assess the acceptance of simultaneously receiving the seasonal influenza vaccine (SIV) and the COVID-19 vaccine in a single administration to reduce vaccine rejection towards the COVID-19 vaccination.

methodsAn online-based cross-section survey was conducted from 1 September to 9 November 2022, in the Eastern Mediterranean Region (EMR) through distributing the survey on different social media platforms, including Facebook, Twitter, LinkedIn and WhatsApp. We used the multi-level model to assess the variation of vaccine countries across EMR countries.

resultsIn total, 3300 participants were included in this survey from 11 countries distributed in the EMR. More than one-third (40.7%) were aged 18-25 years, 60.6% were females, 54.0% had a university degree, 43.1% had previous COVID-19, and 41.9% had relatives or friends who died from COVID-19. In total, 43.3% accepted this combination because it is less costly (9%), safer (18%), more effective (17%), and has fewer doses (19%). Rejection of this combination was due to fear of side effects (31%), and no studies have been published on their effects (31%). There was a significant difference across countries, which accounted for 6% of the variance in the log-odds of accepting the combined vaccination. Multi-level analysis revealed that being male, African and losing a family member or friend from COVID-19 increased the acceptance of the theoretical combined vaccines. Additionally, the number of doses taken of the COVID-19 and influenza vaccines separately significantly affected the combined vaccine acceptance. However, previous COVID-19 infection and older age reduced the odds of accepting the combined vaccines. Occupational level, social status and educational level didn't significantly affect the acceptance odds.

conclusionsWe can conclude that combining SIV and COVID-19 vaccines in one shot increased the overall acceptance of COVID-19 vaccines among vaccine rejectors.

Indexed as

COVID-19Influenza, HumanInfluenza VaccinesAdolescentAdultCOVID-19 VaccinesCross-Sectional StudiesFemaleHumansMaleMediterranean RegionSeasonsVaccines, CombinedYoung AdultCOVID-19 VaccinesInfluenza VaccinesVaccines, CombinedCOVID-19Eastern Mediterranean Regionhealth promotionseasonal influenza vaccinevaccine hesitancy

Identifiers

PMID38019773
PMCPMC10836265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.